References

Feasibility and efficacy of repeated chemotherapy for progressive pediatric low-grade gliomas

10.1002/pbc.22917 · 2011 · External reference

Clinical and treatment factors determining long-term outcomes for adult survivors of childhood low-grade glioma: a population-based study

10.1002/cncr.29907 · 2016 · External reference

Integrated molecular and clinical analysis of 1,000 pediatric low-grade gliomas

10.1016/j.ccell.2020.03.011 · 2020 · External reference

BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomas

10.1172/jci33656 · 2008 · External reference

Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas

10.1158/0008-5472.can-08-2097 · 2008 · External reference

Efficacy and safety of dabrafenib in pediatric patients with BRAF V600 mutation-positive relapsed or refractory low-grade glioma: results from a phase I/IIa study

10.1158/1078-0432.ccr-19-2177 · 2019 · External reference

Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial

10.1016/s1470-2045(19)30277-3 · 2019 · External reference

The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial

10.1038/s41591-023-02668-y · 2024 · External reference

Dabrafenib plus trametinib in pediatric glioma with BRAF V600 mutations

10.1056/nejmoa2303815 · 2023 · External reference

A population-based analysis of the molecular landscape of glioma in adolescents and young adults reveals insights into gliomagenesis

10.1038/s43018-025-00962-x · 2025 · External reference

10.1093/neuonc/noag135 · 2026 · Admitted local publication